Processa shareholders approve 3M share increase to Omnibus Incentive Plan; director Islam retires

Processa Pharmaceuticals, Inc.

Shareholders approved amendment to 2019 Omnibus Incentive Plan, raising share authorization from 3M to 6M shares.
Dr. Khalid Islam retired from the Board effective as of the July 11, 2022 Annual Meeting.
All five director nominees were elected; say-on-pay and auditor ratification passed.
BD & Company, Inc. ratified as independent auditor for 2022.

item 5.02 item 5.07 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Khalid Islam

member of the Board of Directors

PCSA · Processa Pharmaceuticals, Inc.

Effective: 2022-07-11
Filed: July 14, 2022, 7:59 PM ET

Dr. Khalid Islam, who served as a member of the Board of Directors of the Company (the “Board”) since November 2020, retired from the Board Company effective as of the Annual Meeting.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Khalid Islam retired as member of the Board of Directors at Processa Pharmaceuticals, Inc..

Action: retired
Role: member of the Board of Directors

Exact text from the filing

Dr. Khalid Islam, who served as a member of the Board of Directors of the Company (the “Board”) since November 2020, retired from the Board Company effective as of the Annual Meeting.

View on SEC.gov

Processa Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-019301

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.